Claim Amendments

By the present amendment, claims 6, 17, 21, 31-33, 38, 49-51 and have been

withdrawn as being directed to non-elected subject matter. Claim 47 has been

cancelled herein.

Claim 46 has been amended to delete the terms "(racumen)", N-

nitrosodialkylamine, miconazole, clortrimazole and pilocarpine.

Claim 48 has been amended to change its dependency to claim 46.

Claim 52 has been amended to correct a typographical error in the spelling of the

word "cotinine".

Claim 55 is a new claim depending on claim 46 specifying that the imidazole

antimycotic is selected from miconazole and clotrimazole. Support for the is claim is

found in previous claim 46.

The claim amendments have been made without prejudice and without

acquiescing to any of the Examiner's objections. The Applicants submit that no new matter has been entered by the present amendment and entry of the amendments is

respectfully requested. The Applicants reserve the right to file any of the cancelled

respectfully requested. The Applicants reserve the right to life any of the cancelle

subject matter in a divisional patent application.

The Official Action dated October 19, 2006 has been carefully considered. It is

believed that the claims submitted herewith and the following comments represent a

complete response to the Examiner's comments and place the present application in

condition for allowance. Reconsideration is respectfully requested.

7

Appl. No. 10/715,548 Response dated December 18, 2006

Reply to Office action of October 19, 2006

Applicants provisionally elect the subject matter of Group VI, namely claims 39-

48 and 52-53, for initial examination in this application. The election is made with traverse as the Examiner has not established that searching the different methods along

with the composition claims would be an undue burden upon the Office.

The Examiner has also required, for search purposes, the election of a single

disclosed species for the different disorders recited in claim 42 and the different

compounds recited in claims 46 and 51. In response, the Applicants elects nicotine use

disorders and methoxsalen, respectfully.

The Applicants submit that the information provided herein is fully responsive to

the Examiner's requests and invites the Examiner to contact Patricia Folkins at 416-

957-1683 if any further information is needed.

Early and favorable action on the merits is awaited.

Respectfully submitted,

BERESKIN & PARR

By Patricia Folking

Reg. No. 51.379

Bereskin & Parr

Box 401, 40 King Street West

Toronto, Ontario Canada M5H 3Y2 Tel: 416-957-1683

Fax: 905-814-0031

8